Please try another search
For the nine months ended 30 September 2019, Veloxis Pharmaceuticals AS revenues increased 97% to $54.5M. Net income totaled $7.7M vs. loss of $4.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions.
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Revenue | 21.31 | 18.98 | 14.26 | 11.74 |
Gross Profit | 17.39 | 15.46 | 11.51 | 9.09 |
Operating Income | 5.73 | 2.26 | 0.51 | -1.16 |
Net Income | 5.5 | 2.14 | 0.11 | -1.15 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Total Assets | 97.99 | 87.55 | 78.8 | 77.12 |
Total Liabilities | 79.32 | 76.87 | 72.54 | 72.5 |
Total Equity | 18.67 | 10.68 | 6.26 | 4.61 |
Period Ending: | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 2.3 | -0.66 | -2.9 | -11.27 |
Cash From Investing Activities | -0.26 | -0.08 | -0.08 | -0.25 |
Cash From Financing Activities | 2.5 | 1.48 | 0.9 | 34.37 |
Net Change in Cash | 4.36 | 0.72 | -2.13 | 22.75 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review